A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC
ALERT-lung: Alectinib for the treatment of pretreated RET-rearranged advanced non-small cell lung cancer
The RET gene encodes for a transmembrane receptor with tyrosine kinase activity. It is involved in cell proliferation, migration, differentiation, and in neuronal navigation. RET rearrangements occur in 1%-2% of patients with adenocarcinoma. Alectinib is a highly selective next generation ALK inhibitor that has demonstrated potent anti-tumour activity in RET rearranged NSCLC in preclinical studies and early phase trials.
The aim of this trial was to evaluate the activity of alectinib as second-line treatment of pre-treated RET-rearranged advanced NSCLC.
Trial Scheme
